Celera Product Development Will Be Emphasized Following Venter’s Exit
This article was originally published in The Gray Sheet
Executive Summary
Celera Genomics President and Chief Scientific Officer Craig Venter's decision to step down as head of the Applera Corp. subsidiary underscores Celera's shift toward drug discovery and diagnostics development and away from selling subscriptions to its genomic database
You may also be interested in...
Celera Diagnostics To Develop Genetic Tests For Hospitals And Labs
Celera Diagnostics will develop genetic tests aimed at the $1 bil. molecular diagnostic market, which is currently growing at a 30% clip, as part of a recently launched business strategy to commercialize products based on analysis of the human genome.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.